Clinical Application of CTDNA in Operable Breast Cancer Patients
|ClinicalTrials.gov Identifier: NCT02797652|
Recruitment Status : Unknown
Verified June 2016 by Qiang SUN, Peking Union Medical College Hospital.
Recruitment status was: Recruiting
First Posted : June 13, 2016
Last Update Posted : June 14, 2016
|Condition or disease||Intervention/treatment|
|Breast Cancer||Procedure: Neoadjuvant chemotherapy before surgery Procedure: Surgery followed by adjuvant chemotherapy|
|Study Type :||Observational|
|Estimated Enrollment :||60 participants|
|Official Title:||Clinical Application of CTDNA in Operable Breast Cancer Patients|
|Study Start Date :||May 2016|
|Estimated Primary Completion Date :||April 2018|
ctDNA of operable breast cancer patients with neoadjuvant chemotherapy before surgery in different periods: before neo-chemotherapy, during neo-chemotherapy, on surgery day, after surgery and follow-up time.
Procedure: Neoadjuvant chemotherapy before surgery
The operable breast cancer patients takes neoadjuvant chemotherapy before surgery.
ctDNA of operable breast cancer patients with surgery followed by adjuvant chemotherapy in different periods: on surgery day, after surgery, before adjuvant chemotherapy, during adjuvant chemotherapy, and follow-up time.
Procedure: Surgery followed by adjuvant chemotherapy
The operable breast cancer patients takes surgery followed by adjuvant chemotherapy.
- The number of ctDNA copies per milliliter in patients' peripheral blood [ Time Frame: 2 years ]The number of ctDNA copies per milliliter in patients' peripheral blood of neoadjuvant chemotherapy group and surgery group in different periods
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02797652
|Contact: Qiang Sun, Doctorfirstname.lastname@example.org|
|Contact: Li Peng, Doctoremail@example.com|
|Peking Union Medical College Hospital||Recruiting|
|Beijing, Beijing, China, 100730|
|Contact: Qiang Sun, Doctor 86-010-69152701 firstname.lastname@example.org|
|Contact: Li Peng, Doctor 86-010-69152701 email@example.com|
|Principal Investigator: Yidong Zhou, Doctor|
|Sub-Investigator: Li Peng, Doctor|
|Principal Investigator:||Qiang Sun, Doctor||Peking Union Medical College Hospital|